# Kiniksa Pharmaceuticals
 (stock symbol: KNSA) Logo in transparent PNG format

## Kiniksa Pharmaceuticals
 Logo large

### Kiniksa Pharmaceuticals
 Logo large Download PNG (63.74 KB)

![Kiniksa Pharmaceuticals
 Logo large Download PNG (63.74 KB)](/img/orig/KNSA_BIG-d86ef1d6.png)

## Kiniksa Pharmaceuticals
 Logo icon format

### Kiniksa Pharmaceuticals
 Logo icon format Download PNG (21.63 KB)

![Kiniksa Pharmaceuticals
 Logo icon format Download PNG (21.63 KB)](/img/orig/KNSA-7d2da1c3.png)

## About Kiniksa Pharmaceuticals


Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

1. Website domain: kiniksa.com
2. Employees: 215
3. Marketcap: $0.74 Billion USD


## Categories
- [x] ðŸ‡§ðŸ‡²
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
